Orthocell secures $17m to fund US entry
Orthocell (ASX:OCC) has secured $17m in a recent capital raising initiative, aimed at funding the US launch of its flagship Remplir device.
Read MoreTag: OCC
Orthocell (ASX: OCC) – Webinar presentation
Paul Anderson – Managing DIrector – Orthocell is a world-leading regenerative medicine company providing innovative products to restore mobility, function and performance.
Read MoreOrthocell – The Next Big Winner In The Regenerative Sector
With the momentum and remarkable results from OCC trials emerging, I think the timing is right to be accumulating Orthocell.
Read More
